Patents by Inventor Kenneth Bayles

Kenneth Bayles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220339279
    Abstract: Disclosed are recombinant proteins, compositions, vectors, kits, data analyses, and methods for inducing an immune response against, or detecting exposure to, SARS-CoV-2. In particular, the compositions, vectors, kits, data analyses and methods may be utilized to immunize subjects against disease associated with SARS-CoV-2 infection or to protect subjects from SARS-CoV-2 infection. In some embodiments, the recombinant proteins are useful in the production of antibodies against SARS-CoV-2, and for the detection of exposure to SARS-CoV-2.
    Type: Application
    Filed: April 15, 2022
    Publication date: October 27, 2022
    Inventors: Kenneth Bayles, Gloria Borgstahl, Siddappa Byrareddy, Chittibabu Guda, St. Patrick Reid, Mara Jana Broadhurst, Andrew Schnaubelt
  • Patent number: 10954192
    Abstract: Provided herein are pyrrolomycin derivatives, which can be used to modulate Mcl-1, inhibit proliferation of bacteria and pathogens, as well as to treat infectious diseases and cancers.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: March 23, 2021
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Kenneth Bayles, Rongshi Li, Yan Liu
  • Publication number: 20190330147
    Abstract: Provided herein are pyrrolomycin derivatives, which can be used to modulate Mcl-1, inhibit proliferation of bacteria and pathogens, as well as to treat infectious diseases and cancers.
    Type: Application
    Filed: July 9, 2019
    Publication date: October 31, 2019
    Inventors: Kenneth Bayles, Rongshi Li, Yan Liu
  • Patent number: 10414725
    Abstract: Provided herein are pyrrolomycin derivatives, which can be used to modulate Mcl-1, inhibit proliferation of bacteria and pathogens, as well as to treat infectious diseases and cancers.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: September 17, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Kenneth Bayles, Rongshi Li, Yan Liu
  • Publication number: 20180194725
    Abstract: Provided herein are pyrrolomycin derivatives, which can be used to modulate Mcl-1, inhibit proliferation of bacteria and pathogens, as well as to treat infectious diseases and cancers.
    Type: Application
    Filed: July 15, 2016
    Publication date: July 12, 2018
    Inventors: Kenneth Bayles, Rongshi Li, Yan Liu
  • Publication number: 20070231841
    Abstract: Methods of increasing cultured cell growth yields and/or protein production from bacterial cell cultures are provided. More particularly, mutant bacterial cells having an alteration in the expression or activity of the cidABC operon, a gene therein, or a homolog or a regulator thereof, and methods for reducing acetic acid/acetate production in cultures are provided, as are methods for increasing cultured cell growth yields and/or protein production employing such cells. Methods for enhancing bacterial cell death and methods for identifying agents that increase the susceptibility of bacteria to cell death are also provided.
    Type: Application
    Filed: May 20, 2005
    Publication date: October 4, 2007
    Inventors: Kenneth Bayles, Toni Patton, Kelly Rice